SCHEMBL25863497

SCHEMBL25863497

C[C@H]1C[C@]2(C)[C@@H](C)CC[C@H]2[C@@H]2CCC3=CC(=O)CC[C@@H]3[C@H]21

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PGR P06401 4/20 0.54
▸ ALDH1A1 P00352 3/20 0.52
▸ SERPINA6 P08185 2/20 0.52
▸ SHBG P04278 2/20 0.52
▸ SLC22A1 O15245 1/20 0.52
▸ THRB P10828 1/20 0.52
▸ AR P10275 3/20 0.46
▸ CYP19A1 P11511 2/20 0.46
▸ HIF1A Q16665 2/20 0.41
▸ MCL1 Q07820 1/20 0.41
▸ CYP1A2 P05177 1/20 0.41
▸ HSD17B10 Q99714 1/20 0.41
▸ LMNA P02545 3/20 0.40
▸ MAPT P10636 1/20 0.40
▸ CYP3A4 P08684 2/20 0.40
▸ ABCB11 O95342 2/20 0.40
▸ TSHR P16473 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40
▸ ESR1 P03372 1/20 0.40
▸ NR3C1 P04150 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21405873 0.88 SERPINA6 (0.65) PGRALDH1A1SERPINA6SHBGSLC22A1
SCHEMBL24102505 0.88 SERPINA6 (0.65) PGRALDH1A1SERPINA6SHBGSLC22A1
SCHEMBL24102420 0.88 SERPINA6 (0.65) PGRALDH1A1SERPINA6SHBGSLC22A1
SCHEMBL3452660 0.88 SERPINA6 (0.65) PGRALDH1A1SERPINA6SHBGSLC22A1
SCHEMBL24102619 0.88 SERPINA6 (0.65) PGRALDH1A1SERPINA6SHBGSLC22A1
SCHEMBL14568701 0.82 PGR (0.60) PGRALDH1A1SERPINA6SHBGSLC22A1
SCHEMBL13125427 0.81 AR (0.54) PGRALDH1A1SERPINA6SHBGSLC22A1
SCHEMBL3453926 0.81 AR (0.54) PGRALDH1A1SERPINA6SHBGSLC22A1
SCHEMBL14946858 0.80 CYP19A1 (0.65) PGRALDH1A1SERPINA6SHBGSLC22A1
SCHEMBL6843517 0.80 CYP19A1 (0.65) PGRALDH1A1SERPINA6SHBGSLC22A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230227492-A1 MONOMERIC AND OLIGOMERIC COMPOUND EMBODIMENTS AS CONTRACEPTIVES AND THERAPIES AND METHODS OF MAKING AND USING THE SAME THE USA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2023-07-20 — — US disclosed
US-20230227492-A1 MONOMERIC AND OLIGOMERIC COMPOUND EMBODIMENTS AS CONTRACEPTIVES AND THERAPIES AND METHODS OF MAKING AND USING THE SAME THE USA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2023-07-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230227492-A1 MONOMERIC AND OLIGOMERIC COMPOUND EMBODIMENTS AS CONTRACEPTIVES AND THERAPIES AND METHODS OF MAKING AND USING THE SAME SHBG, CYP19A1, GNRHR PGR 16/4885ALDH1A1 2941/4885SERPINA6 55/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback